Sebia

Sebia

Sebia traces its roots to 1967 when Robert de Navailles established the company in a Paris suburb to develop clinical electrophoresis equipment. The firm's original insight was that separating proteins in biological fluids — serum, urine, hemoglobin — was becoming a diagnostic bottleneck, and that purpose-built instrumentation could capture a global installed base. Today Sebia remains headquartered in Lisses, France, as a privately held entity that has outlasted multiple ownership cycles, including a period under private equity sponsorship from Cinven and later Montagu Private Equity before its sale to Tethys in 2021 (per Tethys, 2021). Sebia's strategy rests on a closed-system model that pairs its analyzers with proprietary agarose-gel reagents. The firm concentrates on protein-separation diagnostics that detect monoclonal gammopathies, hemoglobinopathies, and other dysproteinemias — conditions tied to multiple myeloma, sickle-cell disease, and chronic inflammation. On the hardware side, the CAPILLARYS and HYDRASYS platforms automate capillary and gel electrophoresis respectively, while the companion Phoresis software standardizes result interpretation. Confirmed regulatory approvals cover markets across the European Union and the United States, and the company actively distributes in emerging markets across Southeast Asia, Latin America, and the Middle East. In clinical labs, switching vendors is costly because workflow integration and staff retraining create structural stickiness, reinforcing Sebia's recurring revenue anatomy. The company operates a direct-commercial footprint in over a dozen countries, supported by manufacturing and R&D facilities in France. Sebia does not publicly disclose revenue or AUM, but Tethys, a European healthcare growth investor, acquired a majority stake in 2021 in a transaction that valued the company within the mid-cap healthcare-technology range (per Tethys, 2021). The 2021 Tethys acquisition provided a clean ownership transition and recapitalized the balance sheet for expanded international commercial execution. Sebia's adjacent clinical focus includes the launch of the MINICAP FLEX-PIERCING instrument, which adds pre-analytical automation for high-throughput immunology labs, and moves into mass spectrometry-based solutions to complement electrophoretic separations. Sebia's structural differentiator is its single-category dominance in a diagnostic subfield where regulatory moats and installed-base inertia create near-durable recurring revenue. Unlike diversified in-vitro diagnostic conglomerates that treat electrophoresis as one division among many, Sebia concentrates its entire R&D budget and salesforce on agarose-gel and capillary protein separation. This focus yields short product-release cycles and deep clinical-lab relationships that conglomerates cannot replicate. The Tethys ownership structure maintains the firm as a standalone entity with a pure-play mandate, avoiding dilution of its niche identity in favor of the conglomerate model pursued by competitors (per Tethys, 2021).